Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials.
Sumit Sharma, Dilsher S Dhoot, Dilraj S Grewal et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of Phase III trials evaluated the effects of time from diagnosis to treatment and baseline vision on outcomes in patients with macular edema following central or branch retinal vein occlusion. In COPERNICUS, mean best-corrected visual acuity (BCVA) gains at week 24 were 19.8 letters for <1 month, 15.6 letters for 1-3 months, and 11.9 letters for >3 months post-diagnosis, with a significant difference of +7.9 letters (P = 0.01) between the <1 and >3-month groups.
Key findings
- Mean BCVA gains at week 24 were 19.8, 15.6, and 11.9 letters for <1, 1-3, and >3 months post-diagnosis, respectively.
- The difference in BCVA gains between <1 month and >3 months was +7.9 letters (P = 0.01).
- Final BCVA was lower for baseline BCVA T1 compared to T2/T3 (49.8 vs. 60.9/71.2 letters).
- CST decrease from baseline at week 24 was similar across time-since-diagnosis subgroups.
Why it matters
Understanding the relationship between time to treatment and baseline vision can help clinicians set realistic expectations for visual outcomes in patients with retinal vein occlusion, potentially guiding timely intervention strategies.